Compare FRST & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | INDP |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 438.4M |
| IPO Year | 2006 | 2021 |
| Metric | FRST | INDP |
|---|---|---|
| Price | $15.48 | $2.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $18.94 | N/A |
| AVG Volume (30 Days) | 110.1K | ★ 563.6K |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.97 | N/A |
| Revenue Next Year | $8.75 | N/A |
| P/E Ratio | $22.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.68 | $0.92 |
| 52 Week High | $16.88 | $5.96 |
| Indicator | FRST | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 50.79 |
| Support Level | $15.46 | $2.24 |
| Resistance Level | $15.80 | $2.96 |
| Average True Range (ATR) | 0.32 | 0.35 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 71.84 | 45.35 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.